Increased susceptibility to phenytoin teratogenicity: Excessive generation of reactive oxygen species or impaired antioxidant defense?

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 4, 2006, Pages 305-311

  Azarbayjani, Faranak ^a   Borg, L A Håkan ^a   Danielsson, Bengt R ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CATALASE; GLUTATHIONE PEROXIDASE; PHENYTOIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SENSITIVITY; EMBRYO; EMBRYOTOXICITY; FEMALE; FETOTOXICITY; HEART ARRHYTHMIA; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REOXYGENATION; SPIN TRAPPING; STRAIN DIFFERENCE; TERATOGENICITY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; EMBRYO; EMBRYO, MAMMALIAN; FEMALE; MICE; MICE, INBRED A; MICE, INBRED C57BL; PHENYTOIN; PREGNANCY; REACTIVE OXYGEN SPECIES; TERATOGENS;

ANIMALIA;

EID: 33750063190     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_416.x     Document Type: Article

References (51)

1. Abrahamsson, C., M. Palmer, B. Ljung, G. Duker, C. Bäärnhielm, L. Carlsson & B. Danielsson: Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc. Res. 1994, 28, 337-344.
2. Allen, R. G. & A. K. Balin: Oxidative influence on development and differentiation: An overview of a free radical theory of development. Free Radic. Biol. Med. 1989, 6, 631-661.
3. Amicarelli, F., G. M. Tiboni, S. Colafarina, A. Bonfigli, E. Iammarrone, M. Miranda & C. Di Ilio: Antioxidant and GSH-related enzyme response to a single teratogenic exposure to the anticonvulsant phenytoin: Temporospatial evaluation. Teratology 2000, 62, 100-107.
4. + channels resulting in hypoxia-reoxygenation damage. Teratology 2001, 63, 152-160.
5. Ban, Y., R. Konishi, K. Kawana, T. Nakatsuka, T. Fujii & J. M Manson: Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch. Toxicol. 1994, 69, 65-71.
6. Bensinger, R. E. & C. M. Johnson: Luminol assay for superoxide dismutase. Anal. Biochem. 1981, 116, 142-145.
7. Bronsky, P. T., M. C. Johnston & K. K. Sulik: Morphogenesis of hypoxia-induced cleft lip in CL/Fr mice. J. Craniofacial Genet. Dev. Biol. Suppl. 1986, 2, 113-128.
8. Chen, G., M. Griffin, J. L. Poyer, P. B. McCay & D. W. A. Bourne: HPLC procedure for the pharmacokinetic study of the spin-trapping agent, α-phenyl-N-tert-butyl nitrone (PBN). Free Radic. Biol. Med. 1990, 9, 93-98.
9. Danielsson, B. R., F. Azarbayjani, A.-C. Sköld & W. S. Webster: Initiation of phenytoin teratogenesis: Pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation. Teratology 1997, 56, 271-281.
10. Danielsson, B. R. G., M. Danielson, E. Rundqvist & S. Reiland: Identical phalangeal defects induced by phenytoin and nifedipine suggest fetal hypoxia and vascular disruption behind phenytoin teratogenicity. Teratology 1992, 45, 247-258.
11. Danielsson, B. R., A. Johansson, C. Danielsson, F. Azarbayjani, B. Blomgren & A.-C. Sköld: Phenytoin teratogenicity: Hypoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanism. Birth Defects Res. (Part A) Clin. Mol. Teratol. 2005, 73, 146-153.
12. Danielsson, B. R., A.-C. Sköld, F. Azarbayjani, I. Öhman & W. Webster: Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to fetal hydantoin syndrome in rats. Toxicol. Appl. Pharmacol. 2000, 163, 164-175.
13. Danielsson, B. R., A.-C. Sköld, A. Johansson, B. Dillner & B. Blomgren: Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol. Appl. Pharmacol. 2003, 193, 168-176.
14. Dansky, L. V. & R. H. Finnell: Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 2: Human studies. Reprod. Toxicol. 1991, 5, 301-335.
15. Davies, M. P., R. H. An, P. Doevendans, S. Kubalak, K. R. Chien & R. S. Kass: Developmental changes in ionic channel activity in the embryonic murine heart. Circ. Res. 1996, 78, 15-25.
16. Fantel, A. G.: Reactive oxygen species in developmental toxicity: Review and hypothesis. Teratology 1996, 53, 196-217.
17. Fantel, A. G., R. E. Person, R. W. Tumbic, T.-D. Nguyen & B. Mackler: Studies of mitochondria in oxidative embryotoxicity. Teratology 1995, 52, 190-195.
18. Finnell, R. H. & L. V. Dansky: Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 1: Animal studies. Reprod. Toxicol. 1991, 5, 281-299.
19. Gibson, J. E. & B. A. Becker: Teratogenic effects of diphenylhydantoin in Swiss-Webster and A-J mice. Proc. Soc. Exp. Biol. Med. 1968, 128, 905-909.
20. Grabowski, C. T.: Embryonic oxygen deficiency - A physiological approach to analysis of teratological mechanisms. In: Advances in teratology, Vol. 4. Ed.: D. H. M. Woollam. Logos Press, London, 1970, pp. 125-169.
21. Hansen, D. K. &M. E. Hodes: Metabolism of phenytoin in teratogenesis-susceptible and -resistant strains of mice. Drug Metab. Dispos. 1983, 11, 21-24.
22. Hanson, J. W.: Teratogen update: Fetal hydantoin effects. Teratology 1986, 33, 349-353.
23. Harris, C.: Hypoxia and altered redox status in embryotoxicity. In: Handbook of experimental pharmacology, Vol. 124. Drug toxicity in embryonic development I: Advances in understanding mechanisms of birth defects: Morphogenesis and processes at risk. Eds.: R. J. Kavlock & G. P. Daston. Springer-Verlag, Berlin, Heidelberg, New York, 1997, pp. 519-548.
24. He, J.-Q., Y. Ma, Y. Lee, J. A. Thomson & T. J. Kamp: Human embryonic stem cells develop into multiple types of cardiac myocytes. Action potential characterization. Circ. Res. 2003, 93, 32-39.
25. Johansson, L. H. & L. A. H. Borg: A spectrophotometric method for determination of catalase activity in small tissue samples. Anal. Biochem. 1988, 174, 331-336.
26. Leist, K. H. & J. Grauwiler: Fetal pathology in rats following uterine-vessel clamping on day 14 of gestation. Teratology 1974, 10, 55-67.
27. Liu, L. & P. G. Wells: In vivo phenytoin-initiated oxidative damage to proteins and lipids in murine maternal hepatic and embryonic tissue organelles: Potential molecular targets of chemical teratogenesis. Toxicol. Appl. Pharmacol. 1994, 125, 247-255.
28. Liu, L. & P. G. Wells: Potential molecular targets mediating chemical teratogenesis: In vitro peroxidase-catalyzed phenytoin metabolism and oxidative damage to proteins and lipids in murine maternal hepatic microsomes and embryonic 9000g supernatant. Toxicol. Appl. Pharmacol. 1995, 134, 71-80.
29. Lowry, O. H., N. J. Rosebrough, A. L. Farr & R. J. Randall: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
30. Marks, T. A. & R. D. Terry: Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratology 1996, 54, 157-164.
31. Martz, F., C. Failinger III & D. A. Blake: Phenytoin teratogenesis: Correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J. Pharmacol. Exp. Therap. 1977, 203, 231-239.
32. McClain, R. M. & L. Langhoff: Teratogenicity of diphenylhydantoin in the New Zealand white rabbit. Teratology 1980, 21, 371-379.
33. McCord, J. M. & I. Fridovich: Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 1969, 244, 6049-6055.
34. Millicovsky, G. & M. C. Johnston: Maternal hyperoxia greatly reduces the incidence of phenytoin-induced cleft lip and palate in A/J mice. Science 1981, 212, 671-672.
35. Nicol, C. J., J. Zielenski, L.-C. Tsui & P. G. Wells: An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis. FASEB J. 2000, 14, 111-127.
36. New, D. A. T.: Whole-embryo culture and the study of mammalian embryos during organogenesis. Biol. Rev. 1978, 53, 81-122.
37. Ozolins, T. R. S., D. L. A. Siksay & P. G. Wells: Modulation of embryonic glutathione peroxidase activity and phenytoin teratogenicity by dietary deprivation of selenium in CD-1 mice. J. Pharmacol. Exp. Therap. 1996, 277, 945-953.
38. Paglia, D. E. & W. N. Valentine: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 1967, 70, 158-169.
39. Puget, K. & A. M. Michelson: Iron containing superoxide dismutases from luminous bacteria. Biochimie 1974, 56, 1255-1267.
40. Schwartz, P. J.: The long QT syndrome. Curr. Probl. Cardiol. 1997, 22, 297-351.
41. Kr-blocker cisapride: Relation to embryonic cardiac arrhythmia. Reprod. Toxicol. 2002, 16, 333-342.
42. Spence, S. G., C. Vetter & C.-M. Hoe: Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos, in vitro. Teratology 1994, 49, 282-292.
43. Tiboni, G. M., F. Giampietro, S. Angelucci, P. Moio, U. Bellati & C. Di Ilio: Additional investigation on the potentiation of phenytoin teratogenicity by fluconazole. Toxicol. Lett. 2003, 145, 219-229.
44. Wang, W. & I. H. Zucker: Cardiac sympathetic afferent reflex in dogs with congestive heart failure. Amer. J. Physiol. 1996, 271, R751-R756.
45. Watkinson, W. P. & G. Millicovsky: Effect of phenytoin on maternal heart rate in A/J mice: Possible role in teratogenesis. Teratology 1983, 28, 1-8.
46. Webster, W. S., P. D. C. Brown-Woodman, M. D. Snow & B. R. G. Danielsson: Teratogenic potential of almokalant, dofetilide, and d-sotalol: Drugs with potassium channel blocking activity. Teratology 1996, 53, 168-175.
47. Wellfelt, K., A.-C. Sköld, A. Wallin & B. R. Danielsson: Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species. Reprod. Toxicol. 1999, 13, 93-101.
48. Wells, P. G., P. M. Kim, R. R. Laposa, C. J. Nicol, T. Parman & L. M. Winn: Oxidative damage in chemical teratogenesis. Mutat. Res. 1997, 396, 65-78.
49. Wells, P. G., J. T. Zubovits, S. T. Wong, L. M. Molinari & S. Ali: Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and α-phenyl-N-tbutylnitrone: Implications for bioactivation by prostaglandin synthetase. Toxicol. Appl. Pharmacol. 1989, 97, 192-202.
50. Winn, L. M. & P. G. Wells: Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: Evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol. Pharmacol. 1995, 48, 112-120.
51. Witchel, H. J. & J. C. Hancox: Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin. Exp. Pharmacol. Physiol. 2000, 27, 753-766.